Skip to main content
SpringerLink
Log in
Book cover

Preventive Oncology for the Gynecologist pp 83–91Cite as

Cytology and HPV Testing in Primary Cervical Cancer Screening

  • Chapter
  • First Online:

  • 486 Accesses

Abstract

Cervical cancer is the only female genital tract cancer which can be diagnosed and treated in precancerous state by simple screening techniques. The incidence of the disease has come down drastically in countries which have successfully implemented the screening programmes. Cytology, visual inspection with acetic acid, visual inspection with Lugol’s iodine and various HPV diagnostic tests have been used alone or in sequencing for screening. With the advent of newer diagnostics tests with better sensitivity and specificity, it has been possible to triage patients more effectively. This has also helped in increasing the screening interval leading to better compliance. Cytology and HPV testing are the two main methods which are universally adopted for primary screening of cervical cancer.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Papanicolaou GN. New cancer diagnosis. In: Proceedings third race betterment conference. Battle Creek, MI: Race Betterment Foundation; 1928. p. 528–34.

    Google Scholar 

  2. Papanicolaou GN. Atlas of exfoliative cytology. Boston: Commonwealth Fund University Press; 1954.

    Google Scholar 

  3. Reagan JW, Seidemann IL, Sarcusa Y. Cellular morphology of carcinoma in situ and dysplasia or atypical hyperplasia of uterine cervix. Cancer. 1953;6:224–35.

    Article  CAS  Google Scholar 

  4. Richart RM. Natural history of cervical intraepithelial neoplasia. Clin Obstet Gynecol. 1968;10:748–84.

    Article  Google Scholar 

  5. National Cancer Workshop. The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnosis. JAMA. 1989;262:931–4.

    Article  Google Scholar 

  6. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol. 1995;14:680–9.

    Article  Google Scholar 

  7. Hartmann K, Hall SA, Nanda K, et al. Systematic evidence review number 25: screening for cervical cancer. Rockville: US Department of Health and Human Services; 2002.

    Google Scholar 

  8. Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001;84:1616–23.

    Article  CAS  Google Scholar 

  9. Hutchinson ML, Zahniser DJ, Sherman ME, et al. Utility of liquid-based cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer. 1999;87:48–55.

    Article  CAS  Google Scholar 

  10. Lee KR, Ashfaq R, Birdson GG, et al. Comparison of conventional Papanicolaou smears and a fluid-based, thin-layer system for cervical cancer screening. Obstet Gynecol. 1997;90:278–84.

    Article  CAS  Google Scholar 

  11. Marino JF, Fremont-Smith M. Direct-to-vial experience with Auto Cyte PREP in a small New England regional cytology practice. J Reprod Med. 2001;46:353–8.

    CAS  PubMed  Google Scholar 

  12. Eversole GM, Moriarty AT, Schwartz MR, et al. Practices of participants in the College of American Pathologists interlaboratory comparison program in cervicovaginal cytology, 2006. Arch Pathol Lab Med. 2010;134:331–5.

    PubMed  Google Scholar 

  13. Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systemic review and meta-analysis. Obstet Gynecol. 2008;111:167–77.

    Article  Google Scholar 

  14. Boulet GA, Horvath CA, Berghmans S, Bogers J. Human papillomavirus in cervical cancer screening: important role as biomarker. Cancer Epidemiol Biomarkers Prev. 2008;17:810–7.

    Article  CAS  Google Scholar 

  15. Wheeler CM, Hunt WC, Schiffman M, Castle PE, Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesions Triage Study Group. Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis. 2006;194:1291–9.

    Article  Google Scholar 

  16. Ungar E, Budgeon LR, Myerson D, et al. Viral diagnosis by in situ hybridization. Am J Surg Pathol. 1986;10:1–8.

    Article  Google Scholar 

  17. Cubie HA, Norval M. Detection of human papillomaviruses in paraffin wax sections with biotinylated synthetic oligonucleotide probes and immunogold staining. J Clin Pathol. 1989;42:988–91.

    Article  CAS  Google Scholar 

  18. Coutlée F, Mayrand MH, Provencher D, Franco E. The future of HPV testing in clinical laboratories and applied virology research. Clin Diagn Virol. 1997;8:123–41.

    Article  Google Scholar 

  19. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol. 2008;9(10):929–36.

    Article  Google Scholar 

  20. Gravitt PE, Schiffman M, Solomon D, Wheeler CM, Castle PE. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol Biomarkers Prev. 2008;17:1248–54.

    Article  CAS  Google Scholar 

  21. Heideman DA, Hesselink AT, Berkhof J, et al. Clinical validation of the cobas® 4800 HPV Test for cervical screening purposes. J Clin Microbiol. 2011;49(11):3983–5.

    Article  CAS  Google Scholar 

  22. Swan DC, Tucker RA, Tortolero-Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol. 1999;37:1030–4.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Mayrand MH, Coutlee F, Hankins C, et al. Detection of human papillomavirus type 16 DNA in consecutive genital samples does not always represent persistent infection as determined by molecular variant analysis. J Clin Microbiol. 2000;38:3388–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Molden T, Kraus I, Skomedal H, Nordstrøm T, Karlsen F. PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J Virol Methods. 2007;142(1-2):204–12.

    Article  CAS  Google Scholar 

  25. Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147–72.

    Article  Google Scholar 

  26. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12(7):663–72.

    Article  Google Scholar 

  27. Dijkstra MG, van Zummeren M, Rozendaal L, et al. Safety of extending screening intervals beyond five years in cervical screening programmed with testing for high risk human papillomavirus: 14-year follow-up of population based randomized cohort in the Netherlands. BMJ. 2016;355:i4924.

    Article  Google Scholar 

  28. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52(6):342–62.

    Article  Google Scholar 

  29. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004;103(4):619–31.

    Article  Google Scholar 

  30. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. N Engl J Med. 2007;357(16):1579–88.

    Article  CAS  Google Scholar 

  31. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine. 2012;30(Suppl 5):F88–99.

    Article  Google Scholar 

  32. Kitchener HC, Gilham C, Sargent A, et al. A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: extended follow up in the ARTISTIC trial. Eur J Cancer. 2011;47:864–71.

    Article  Google Scholar 

  33. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;125(2):330–7.

    Google Scholar 

  34. Castle PE, Rodriguez AC, Burk RD, et al. Short-term persistence and risk of cervical precancer and cancer: population-based cohort study. BMJ. 2009;339:b2569.

    Article  Google Scholar 

  35. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested sub study of the NTCC randomized controlled trial. Lancet Oncol. 2013;14:168–76.

    Article  Google Scholar 

  36. Arbyn M, Roelens J, Cuschieri K, et al. The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer. 2013;132:101–8.

    Article  CAS  Google Scholar 

  37. Strander B, Andersson-Ellstrom A, Milsom I, et al. Long-term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: population-based cohort study. BMJ. 2007;335:1077.

    Article  Google Scholar 

  38. Rebolj M, Helmerhorst T, Habbema D, et al. Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population-based cohort study. BMJ. 2012;345:e6855.

    Article  Google Scholar 

  39. Kocken M, Helmerhorst TJM, Berkhof J, Louwers JA, Nobbenhuis MAE, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol. 2011;12(5):441–50.

    Article  Google Scholar 

  40. Arbyn M, Paraskevaidis E, Martin-Hirsche P, et al. Clinical utility of HPV–DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol. 2005;99:S7–11.

    Article  CAS  Google Scholar 

  41. Chan BKS, Melnikow J, Slee CA, et al. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am J Obstet Gynecol. 2009;200:422.e1–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynae-Oncology, Dharamshila Narayana Superspeciality Hospital, New Delhi, India

    Satinder Kaur & Shilpa Jamwal

Authors
  1. Satinder Kaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shilpa Jamwal
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Babu Jagjivan Ram Memorial Hospital, New Delhi, India

    Sumita Mehta

  2. Department of Obstetrics and Gynecology, University College of Medical Sciences and Guru Teg Bahadur Hospital, New Delhi, India

    Anshuja Singla

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Kaur, S., Jamwal, S. (2019). Cytology and HPV Testing in Primary Cervical Cancer Screening. In: Mehta, S., Singla, A. (eds) Preventive Oncology for the Gynecologist. Springer, Singapore. https://doi.org/10.1007/978-981-13-3438-2_7

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-3438-2_7

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-13-3437-5

  • Online ISBN: 978-981-13-3438-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation